- Home
- CLDX vs JANX Comparison
CLDX vs JANX Comparison
Compare CLDX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- JANX
- Stock Information
- Founded
- CLDX N/A
- JANX 2017
- Country
- CLDX United States
- JANX United States
- Employees
- CLDX N/A
- JANX N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- JANX Health Care
- Exchange
- CLDX Nasdaq
- JANX Nasdaq
- Market Cap
- CLDX 1.3B
- JANX 1.4B
- IPO Year
- CLDX 2008
- JANX 2021
- Fundamental
- Price
- CLDX $20.66
- JANX $22.83
- Analyst Decision
- CLDX Buy
- JANX Strong Buy
- Analyst Count
- CLDX 9
- JANX 8
- Target Price
- CLDX $50.00
- JANX $90.63
- AVG Volume (30 Days)
- CLDX 843.8K
- JANX 851.8K
- Earning Date
- CLDX 08-07-2025
- JANX 08-07-2025
- Dividend Yield
- CLDX N/A
- JANX N/A
- EPS Growth
- CLDX N/A
- JANX N/A
- EPS
- CLDX N/A
- JANX N/A
- Revenue
- CLDX $5,790,000.00
- JANX $439,000.00
- Revenue This Year
- CLDX N/A
- JANX N/A
- Revenue Next Year
- CLDX N/A
- JANX $1,470.83
- P/E Ratio
- CLDX N/A
- JANX N/A
- Revenue Growth
- CLDX N/A
- JANX N/A
- 52 Week Low
- CLDX $14.40
- JANX $22.25
- 52 Week High
- CLDX $47.00
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CLDX 40.75
- JANX 39.45
- Support Level
- CLDX $20.65
- JANX $23.17
- Resistance Level
- CLDX $22.60
- JANX $26.50
- Average True Range (ATR)
- CLDX 1.11
- JANX 1.54
- MACD
- CLDX -0.28
- JANX -0.31
- Stochastic Oscillator
- CLDX 10.64
- JANX 11.46
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.